A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

(MedPage Today) -- An oral investigational agent, gildeuretinol (ALK-001), demonstrated a significant reduction in geographic atrophy (GA) lesion growth and improvements in low luminance visual function in the phase II SAGA trial, according to...